<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959306</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL14</org_study_id>
    <nct_id>NCT03959306</nct_id>
  </id_info>
  <brief_title>Efficacy of Black Seed Oil in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Effect of Black Seed Oil on Markers of Endothelial Dysfunction in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of black seed oil on markers of
      endothelial dysfunction in patients with type 2 diabetes mellitus .Also, to investigate its
      effect on glycemic control ,lipid profile and quality of life of those patients .
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2019</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on Markers of Endothelial Dysfunction(The change in the level of soluble intercellular adhesion molecule ( ICAM) in serum using ELISA kit)</measure>
    <time_frame>three months</time_frame>
    <description>it will be assessed at baseline and after three months of treatment ( to determine the change from baseline at three months ) to determine whether it is effective in reducing marker of endothelial dysfunction (ICAM) in patients with type 2 diabetes mellitus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on Glycemic Control (Measurement of fasting blood glucose )</measure>
    <time_frame>three months</time_frame>
    <description>it will be assessed at baseline and after three months of treatment to determine the anti-diabetic effect of black seed oil ( if it is effective in reducing fasting blood glucose from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Glycemic Control (Measurement of glycated hemoglobin)</measure>
    <time_frame>three months</time_frame>
    <description>it will be assessed at baseline and after three months of treatment to determine the anti-diabetic effect of black seed oil ( if it is effective in reducing glycated hemoglobin from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Lipid Profile ( Measurement of TC,TG, HDL-C,LDL-C)</measure>
    <time_frame>three months</time_frame>
    <description>it will be assessed at baseline and after three months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Inflammatory Status ( Measurement of High sensitive C-Reactive Protein using ELISA kit)</measure>
    <time_frame>three months</time_frame>
    <description>it will be assessed at baseline and after three months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Quality of Life ( Using Diabetes-39 questionnaire )</measure>
    <time_frame>three months</time_frame>
    <description>it will be assessed at baseline and after three months of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>this group of patients will receive their standard anti-diabetic treatment in addition to 1800 mg of black seed oil soft gelatin capsule (900 mg twice daily) for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this group of patients will receive their standard anti-diabetic treatment only</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Black Seed Oil</intervention_name>
    <description>Black seed oil soft gelatin capsule</description>
    <arm_group_label>Group I</arm_group_label>
    <other_name>Nigella sativa oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Diabetics</intervention_name>
    <description>standard anti-diabetic treatment prescribed for the patient</description>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: adult patients with more than or equal 18 years old.

          2. Previous diagnosis of Diabetes mellitus type 2 according to American Diabetes
             Association Criteria (ADA).

          3. Approval to participate and give informed consent.

        Exclusion Criteria:

          1. Unstable coronary artery disease, cardiac arrhythmia or congestive heart failure.

          2. Uncontrolled hypertension or recent stroke.

          3. Chronic kidney disease or chronic liver disease.

          4. Intake of black seed oil during the previous two months or any other antioxidant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 18, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Amany Talaat Abdellatif El-Garf</investigator_full_name>
    <investigator_title>Assistant Lecturer of Clinical Pharmacy, Faculty of Pharmacy</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Black Seed Oil</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

